search
Back to results

Safety and Efficacy of Carpal Stim in Treating Carpal Tunnel Syndrome

Primary Purpose

Carpal Tunnel Syndrome

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
PRF stimulation
Sham stimulation
Sponsored by
GiMer Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carpal Tunnel Syndrome

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female subjects aged ≥ 20 years old during the recruitment phase
  2. Clinical diagnosis of CTS:

    1. Diagnosis of CTS was confirmed by Nerve Conduction Velocity (NCV) but not limited to NCV
    2. Symptoms consistent with CTS for at least 3 months and the numerical rating scale (NRS) score ≥ 5 during the recruitment phase
  3. Willing to abstain from any other treatment or therapy for CTS throughout the trial except protocol-described medications
  4. The subject is willing and able to comply with the procedure and requirements of this trial
  5. The participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with IRB requirements

Exclusion Criteria:

  1. Wrist fractures or cysts at the CTS affected side
  2. Wrist surgery within the past 3 months, especially carpal tunnel release surgery at the CTS affected side
  3. Receiving upper limb (including neck) surgery
  4. Injections of corticosteroids/cortisone into the wrist or hand within the past 3 months
  5. With a past medical history of diabetic polyneuropathy
  6. With a past medical history of rheumatoid arthritis
  7. With a past medical history of epilepsy
  8. Body Mass Index (BMI) > 40 kg/m2
  9. Participation in any investigational study in the last 2 weeks or current enrollment in any trial.
  10. Active infection at the stimulator contact site during the recruitment phase
  11. Pregnant women or diagnosed with postpartum edema in the wrist per investigator's discretion
  12. Patients with implanted medical devices that are electronic products, such as implantable cardioverter defibrillators, pacemakers, spinal cord stimulation systems, or spinal cord drug infusion pumps

Sites / Locations

  • Hualien Tzu Chi Hospital
  • Chung Shan Medical University Hospital
  • National Cheng Kung University Hospital
  • Veterans General Hospital-Taipei
  • Linkou Chang Gung Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Active Comparator

Arm Label

Sham Control Group

PRF Group

Arm Description

Subject receiving fake stimulation (no stimulation but same device procedure with PRF group)

Subject receiving 500 KHz PRF stimulation for 15 min

Outcomes

Primary Outcome Measures

Effectiveness: The responder rate of the PRF group and Sham-Control group
Safety: Incidence of adverse events (AEs) and serious AEs (SAEs)
Safety: Change in Nerve Conduction Velocity 14th day compared to baseline
Median nerve sensory latency time change over 20%

Secondary Outcome Measures

Proportion in responder in treatment and sham-controlled groups
Change in NRS score in treatment and sham-controlled groups compared to baseline
Change in PGIC scale in treatment and sham-controlled compared to baseline
Change in GSS score in treatment and sham-controlled compared to baseline
Change in BCTQ-SSS score in treatment and sham-controlled compared to baseline
Change in BCTQ-FSS score in treatment and sham-controlled compared to baseline

Full Information

First Posted
August 9, 2022
Last Updated
February 23, 2023
Sponsor
GiMer Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT05497037
Brief Title
Safety and Efficacy of Carpal Stim in Treating Carpal Tunnel Syndrome
Official Title
A Prospective, Multicenter, Randomized, Double-Blind, Two-Arm, Sham-Controlled, Parallel-Design Trial to Assess the Efficacy and Safety of Carpal Stim for Treating Carpal Tunnel Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
March 9, 2022 (Actual)
Primary Completion Date
December 31, 2022 (Actual)
Study Completion Date
February 8, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GiMer Medical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to assess the efficacy and safety of Carpal Stim for pain relief in CTS subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carpal Tunnel Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
58 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sham Control Group
Arm Type
Sham Comparator
Arm Description
Subject receiving fake stimulation (no stimulation but same device procedure with PRF group)
Arm Title
PRF Group
Arm Type
Active Comparator
Arm Description
Subject receiving 500 KHz PRF stimulation for 15 min
Intervention Type
Device
Intervention Name(s)
PRF stimulation
Intervention Description
One time 500 kHZ stimulation for 15 min
Intervention Type
Device
Intervention Name(s)
Sham stimulation
Intervention Description
Sham stimulation for 15 min
Primary Outcome Measure Information:
Title
Effectiveness: The responder rate of the PRF group and Sham-Control group
Time Frame
1 hour after end of stimulation
Title
Safety: Incidence of adverse events (AEs) and serious AEs (SAEs)
Time Frame
Up to 14 days
Title
Safety: Change in Nerve Conduction Velocity 14th day compared to baseline
Description
Median nerve sensory latency time change over 20%
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Proportion in responder in treatment and sham-controlled groups
Time Frame
3, 7, 14 days after end of stimulation
Title
Change in NRS score in treatment and sham-controlled groups compared to baseline
Time Frame
1hr, 3, 7, 14 days after end of stimulation
Title
Change in PGIC scale in treatment and sham-controlled compared to baseline
Time Frame
1hr, 3, 7, 14 days after end of stimulation
Title
Change in GSS score in treatment and sham-controlled compared to baseline
Time Frame
1hr, 3, 7, 14 days after end of stimulation
Title
Change in BCTQ-SSS score in treatment and sham-controlled compared to baseline
Time Frame
14 days after end of stimulation
Title
Change in BCTQ-FSS score in treatment and sham-controlled compared to baseline
Time Frame
14 days after end of stimulation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects aged ≥ 20 years old during the recruitment phase Clinical diagnosis of CTS: Diagnosis of CTS was confirmed by Nerve Conduction Velocity (NCV) but not limited to NCV Symptoms consistent with CTS for at least 3 months and the numerical rating scale (NRS) score ≥ 5 during the recruitment phase Willing to abstain from any other treatment or therapy for CTS throughout the trial except protocol-described medications The subject is willing and able to comply with the procedure and requirements of this trial The participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with IRB requirements Exclusion Criteria: Wrist fractures or cysts at the CTS affected side Wrist surgery within the past 3 months, especially carpal tunnel release surgery at the CTS affected side Receiving upper limb (including neck) surgery Injections of corticosteroids/cortisone into the wrist or hand within the past 3 months With a past medical history of diabetic polyneuropathy With a past medical history of rheumatoid arthritis With a past medical history of epilepsy Body Mass Index (BMI) > 40 kg/m2 Participation in any investigational study in the last 2 weeks or current enrollment in any trial. Active infection at the stimulator contact site during the recruitment phase Pregnant women or diagnosed with postpartum edema in the wrist per investigator's discretion Patients with implanted medical devices that are electronic products, such as implantable cardioverter defibrillators, pacemakers, spinal cord stimulation systems, or spinal cord drug infusion pumps
Facility Information:
Facility Name
Hualien Tzu Chi Hospital
City
Hualien City
Country
Taiwan
Facility Name
Chung Shan Medical University Hospital
City
Taichung
Country
Taiwan
Facility Name
National Cheng Kung University Hospital
City
Tainan
Country
Taiwan
Facility Name
Veterans General Hospital-Taipei
City
Taipei
Country
Taiwan
Facility Name
Linkou Chang Gung Memorial Hospital
City
Taoyuan
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Efficacy of Carpal Stim in Treating Carpal Tunnel Syndrome

We'll reach out to this number within 24 hrs